Astrazzinica works with an artificial intelligence business to develop a cancer property

The British company “Astrazinica” has signed a $ 247 million agreement with the US company “Apsy” to create an anti cancer body, in the latest collaboration in rapid efforts to use artificial intelligence in the pharmaceutical industry. The British newspaper “Financial Times” reported that cooperation is aimed at utilizing the technology of Absci to produce protein on a large -scale analysis and find an effective treatment for crops, which is the main focus of the “Astrazinica” business. The type of cancer targeted by the middle was not revealed, but the agreement is part of the ambitious “Astrazinica” plans to change traditional medicine to advanced and effective medicine. In addition to a series of similarities between major pharmaceutical businesses and emerging artificial intelligence companies, the partnership to build new treatments to treat diseases and reduce the size of their development costs. “The implementation of the engineering principles for the discovery of medicine has contributed to improving the possibilities of success and reducing the time used in the development of the property.” “Collaboration with (APSE) is an exciting opportunity to use experiences with artificial intelligence to create antibodies, and the research also leads to the development of biological engineering,” says Bouja Sabra. He added: “Artificial intelligence technique not only enables us to increase success and exploration opportunities, but also increases the diversity of the biological materials we discover. We apply artificial intelligence to all phases of our discovery and our practical development by building and working together with businesses such as (absi).” Anti -tumor medicines that use different techniques are an important topic for collaboration between leading and smaller pharmaceutical pharmaceutical businesses doing advanced research. In September, the US company “Moderna” agreed on an agreement that is likely to be more than $ 1.7 billion to develop cancer vaccines in collaboration with the German company “Immatics”, which uses “TT cell technology”, with the aim of eliminating cancer -related proteins.